16:06:19 EST Mon 04 Mar 2024
Enter Symbol
or Name

Login ID:
Entheon Biomedical Corp
Symbol ENBI
Shares Issued 59,089,266
Close 2022-11-30 C$ 0.03
Market Cap C$ 1,772,678
Recent Sedar Documents

Entheon to cease HaluGen, Lobo genetic test kit sales

2022-11-30 18:16 ET - News Release

Pladson Subject: Entheon Biomedical - Nov 30 NR Word Document File: '\\office\emailin\20221130 150248 Attachment Entheon - HaluGen Life Sciences and Lobo Genetics Corporate Update 20221130 final.docx' Entheon Provides Corporate Update on HaluGen Life Sciences and Lobo Genetics Vancouver, British Columbia--(November 30XX, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is providing an update on its two wholly-owned subsidiaries, HaluGen Life Sciences Inc. ("HaluGen") and Lobo Genetics Inc. ("Lobo"). As part of Entheon's continued efforts to re-focus resources, Entheon will be ceasing sales of HaluGen and Lobo and Halugen Direct-To-Consumer ("DTC") genetic testing kits to reduce operational costs. Existing customers can continue to access their genetic test results at www.HaluGen.com and www.LoboGene.com. Any additional customer inquiries can be sent to: support@halugen.com and support@lobogene.com.Information related to return of tests and refunds can be found here: XXXXX About HaluGen Life Sciences Inc.gen HaluGen has developed a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, with the goal of improving patient care and reducing side effects and risk. HaluGen's genetic-based psychedelic pre-screening platform helps evaluate an individual's overall sensitivity and risk profile when using hallucinogenic drugs. This platform is the first of its kind with test results within days. https://www.halugen.com About Lobo Genetics Inc. Lobo is a personalized genetics company with a direct-to-consumer (DTC) platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual's response to hallucinogenic and psychoactive drugs. https://www.lobogene.com About Entheon Biomedical Corp. Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders. On Behalf of the Board of Directors, Timothy Ko, CEO, President and Director For more information, please contact the Company at: Entheon Biomedical Corp. Timothy Ko, CEO timothy@entheonbiomedical.com https://entheonbiomedical.com/ Cautionary Note Regarding Forward-Looking Statements This news release includes certain forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein, including, without limitation, statements with respect to its Halugen and Lobo subsidiaries are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Often, but not always, forward-looking information can be identified by words such as "pro forma", "plans", "expects", "will", "may", "should", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", "potential" or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this news release including, without limitation, that the Company's patent applications will be accepted and the benefits of such patents will be realized; that general business and economic conditions will not change in a material adverse manner; that applicable regulatory approvals will be received; and assumptions regarding political and regulatory stability and stability in financial and capital markets. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, that the Company's patent applications will not be accepted; delays in obtaining regulatory approvals (including those of the Canadian Securities Exchange); risks related to the volatility of global capital markets and global economic conditions; and political instability. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does the Company nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither the Company nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. The Canadian Securities Exchange has not approved nor disapproved the contents of this news release. The Canadian Securities Exchange has not approved nor disapproved the contents of this news release NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES

© 2024 Canjex Publishing Ltd. All rights reserved.